Related Experiment Video

Updated: Jun 12, 2025

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

7.8K

Pioneering the Battle Against Breast Cancer: The Promise of New Bcl-2 Family

Ali Farhang Boroujeni1, Zeynep Ates-Alagoz1

  • 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Ankara, Turkey.

Anti-Cancer Agents in Medicinal Chemistry
|September 24, 2024
PubMed

Insights

Novel Bcl-2 inhibitors show promise for breast cancer treatment. These agents target proteins that prevent cancer cell death, offering new therapeutic options for patients in monotherapy or combination settings.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancer is the most common cancer, leading to significant mortality.
  • Cancer cells evade apoptosis by upregulating Bcl-2 family proteins, causing treatment failure.
  • Bcl-2 family proteins are critical regulators of programmed cell death.

Purpose of the Study:

  • To review Bcl-2 family inhibitors in clinical trials for breast cancer.
  • To highlight in vitro findings of novel Bcl-2 inhibitors against breast cancer cells.
  • To assess the potential of Bcl-2 inhibitors as monotherapy or combination therapy.

Main Methods:

  • Review of existing literature on Bcl-2 inhibitors in breast cancer.
  • Analysis of in vitro study results for novel Bcl-2 inhibitors.
  • Examination of clinical trial data for Bcl-2 inhibitors in breast cancer.

Main Results:

  • Bcl-2 family inhibitors have demonstrated efficacy in preclinical breast cancer models.
  • Several Bcl-2 inhibitors are currently undergoing clinical trials for breast cancer.
  • In vitro studies show promising results for novel Bcl-2 inhibitors against breast cancer cells.

Conclusions:

  • Bcl-2 family inhibitors represent a promising therapeutic strategy for breast cancer.
  • These inhibitors can overcome treatment resistance mediated by Bcl-2 proteins.
  • Further clinical investigation is warranted to establish the role of Bcl-2 inhibitors in breast cancer management.
Keywords:
Bcl-2Bcl-2 family inhibitorsBcl-xLMcl-1breast cancer.synthetic scaffolds

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.0K
gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair08:15

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

12.2K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K